Jiangsu CoWin Biotech Co., Ltd. (SHA:688426)
China · Delayed Price · Currency is CNY 20.24
+0.02 (0.10%)
Mar 30, 2026, 4:00 PM EDT
Jiangsu CoWin Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 193.05 | 125.87 | 171.34 | 521.6 | 338.46 |
Other Revenue | - | 0 | - | - | - |
| 193.05 | 125.88 | 171.34 | 521.6 | 338.46 | |
Revenue Growth (YoY) | 53.36% | -26.53% | -67.15% | 54.11% | 45.13% |
Cost of Revenue | - | 62.78 | 67.55 | 160.69 | 95.02 |
Gross Profit | 193.05 | 63.09 | 103.79 | 360.91 | 243.44 |
Selling, General & Admin | - | 130.55 | 132.93 | 99.81 | 71.43 |
Research & Development | - | 99.23 | 88.26 | 74.02 | 38.58 |
Other Operating Expenses | 297.84 | 2.28 | 1.15 | 1.21 | 1.04 |
Operating Expenses | 297.84 | 253.73 | 243.14 | 184.55 | 112.51 |
Operating Income | -104.79 | -190.64 | -139.35 | 176.36 | 130.93 |
Interest Expense | - | -1.39 | -1.7 | -1.93 | -1.92 |
Interest & Investment Income | - | 20.71 | 24.43 | 9.13 | 7.53 |
Currency Exchange Gain (Loss) | - | 0.43 | 0.52 | 6.08 | -1.09 |
Other Non Operating Income (Expenses) | -2.53 | -0.07 | -0.06 | -0.12 | -0.3 |
EBT Excluding Unusual Items | -107.32 | -170.97 | -116.16 | 189.52 | 135.16 |
Impairment of Goodwill | - | - | -4.27 | - | - |
Gain (Loss) on Sale of Investments | - | 3.6 | 13.41 | 1.59 | 0.42 |
Gain (Loss) on Sale of Assets | - | -0.21 | 1.24 | -0.51 | 1.26 |
Asset Writedown | - | -3.04 | - | -0.06 | - |
Other Unusual Items | - | 5.91 | 12.8 | 4.86 | 7.69 |
Pretax Income | -107.32 | -164.7 | -92.98 | 195.4 | 144.53 |
Income Tax Expense | -4.04 | -3.33 | -9.24 | 24.82 | 18.68 |
Earnings From Continuing Operations | -103.28 | -161.38 | -83.74 | 170.57 | 125.85 |
Minority Interest in Earnings | - | 4.17 | -0.67 | -11.31 | - |
Net Income | -103.28 | -157.21 | -84.41 | 159.26 | 125.85 |
Net Income to Common | -103.28 | -157.21 | -84.41 | 159.26 | 125.85 |
Net Income Growth | - | - | - | 26.55% | 16.36% |
Shares Outstanding (Basic) | 110 | 111 | 113 | 92 | 84 |
Shares Outstanding (Diluted) | 110 | 111 | 113 | 93 | 84 |
Shares Change (YoY) | -1.45% | -0.93% | 21.20% | 10.07% | 20.59% |
EPS (Basic) | -0.94 | -1.41 | -0.75 | 1.72 | 1.50 |
EPS (Diluted) | -0.94 | -1.41 | -0.75 | 1.72 | 1.49 |
EPS Growth | - | - | - | 14.97% | -3.24% |
Free Cash Flow | - | -161.67 | -170.94 | 6.99 | 20.11 |
Free Cash Flow Per Share | - | -1.45 | -1.52 | 0.07 | 0.24 |
Dividend Per Share | - | - | - | 0.433 | - |
Gross Margin | 100.00% | 50.12% | 60.58% | 69.19% | 71.92% |
Operating Margin | -54.28% | -151.45% | -81.33% | 33.81% | 38.69% |
Profit Margin | -53.50% | -124.89% | -49.26% | 30.53% | 37.18% |
Free Cash Flow Margin | - | -128.44% | -99.77% | 1.34% | 5.94% |
EBITDA | -76.38 | -162.23 | -115.84 | 189.71 | 138.85 |
EBITDA Margin | -39.57% | -128.88% | -67.61% | 36.37% | 41.02% |
D&A For EBITDA | 28.41 | 28.41 | 23.51 | 13.35 | 7.91 |
EBIT | -104.79 | -190.64 | -139.35 | 176.36 | 130.93 |
EBIT Margin | -54.28% | -151.45% | -81.33% | 33.81% | 38.69% |
Effective Tax Rate | - | - | - | 12.71% | 12.93% |
Revenue as Reported | - | 125.88 | 171.34 | 521.6 | 338.46 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.